Sinovac Biotech

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness.  However, shots from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and AstraZeneca plc (NASDAQ: AZN) demonstrated better protection rates, reported Reuters.

Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced a paper, titled “A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv. The findings suggest a third dose of CoronaVac® can induce a better neutralization breadth to variants of concern (“VOCs”), including the Delta variant, a rapid immunologic

New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (“SINOVAC”), a subsidiary of the Company, received approval from the Public Health Institute of Chile (“ISP”) for emergency use for children and adolescents aged between 6 and 17. ISP Director Heriberto Garcia made the annou

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of two papers, which are available on Medrxiv. The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac® in two- and three-dose schedules. The results indicate that a third booster dose of CoronaVac® induces a strong immune response in healthy adults with

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval from the National Medical Product Administration of China (“NMPA”) for its Sabin strain based inactivated polio vaccine (Vero cells) ("sIPV") on July 12, 2021. The vaccine is expected to be available on the market by the end of 2021. SINOVAC also submitted an application for prequalification

SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi), which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac®for distribution through the COVAX Facility. According to the APA, SINOVAC will supply 50 million doses of CoronaVac® by t

SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac®, in healthy children and adolescents aged 3-17 in China. The double-blind, randomized, placebo-controlled study evaluated the safety, tolerability and immunogenicity of Cor

The Lancet Infectious Diseases Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old

Wuxi Biologics Cayman Inc

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments.

Pandemic Accelerates China's Drive Into mRNA Treatments

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (“SINOVAC”), a subsidiary of the Company, was approved for emergency use under the World Health Organization (“WHO”) Emergency Use Listing (“EUL”) procedure. Prior to this, the Strategic Advisory Group of Experts on Immuniza

World Health Organization Authorizes SINOVAC's CoronaVac® for Emergency Use

BeiGene

Galmed Pharmaceuticals

Novavax

Shineco

The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V.

Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million,

Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac's annual capacity of CoronaVac® has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. I

Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine

Moderna

Pfizer

AstraZeneca

BioNTech SE

CureVac B.V

Johnson & Johnson

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovac's COVID-19 vaccine in individuals aged 18 and above. Sinovac began rolling submission to the NMPA since September 2020 and the NMPA carried out rolling reviews when the submission w

Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on July 21, 2020. Trials were conducted in Brazil, Turkey, Indonesia, and Chile. In compliance with the principles of Good Clinical Practice (GCP), the trials were conducted with the vaccine candidate produced from the same lot and follo

Sinovac Announces Phase III Results of Its COVID-19 Vaccine

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has officially filed for conditional market authorization for CoronaVac, the COVID-19 vaccine, with China's National Medical Products Administration (NMPA). The vaccine candidate was tested in phase III clinical studies outside of China. The preliminary results of the trials demonstrated a good safety profile for the vaccin

Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China

BEIJING and BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- 1Globe Capital LLC (“1GlobeCap”), a principal and long-term shareholder of Sinovac Biotech (NASDAQ: SVA) (“Sinovac”), has reached agreement with the Securities and Exchange Commission (“SEC”) to end investigation of its 13D form compliance.

1Globe Capital, the Largest Shareholder of Sinovac Biotech, Reached Agreement with SEC and Calls on All Stakeholders to Support Sinovac's COVID-19 Vaccine Program

Immutep Ltd

JD.com

JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported Sino Biopharma of Hong Kong will invest $515 million in a Sinovac subsidiary to double production of its inactivated COVID-19 vaccine, CoronaVac.

Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company's 23-Valent Pneumococcal Polysaccharide (“PPV”) Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above. Mr. Weidong Yin, Chairman, President and CEO of Sinova

Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial Summary Sales for the third quarter of 2020 were $115.5 million, an increase of 79.4% from $64.3 million in the prior year period. Sales for the nine months ended September 30, 2020, were $183.2 million

Sinovac Reports Unaudited Third Quarter 2020 Financial Results

The company hopes to produce 600 million doses of its CoronaVac vaccine a year, enough for 300 million people.

China's Sinovac To Double Covid-19 Vaccine Output Anticipating Regulatory Approval

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinovac Life Sciences Co., Ltd. (“Sinovac LS”) (formerly known as Sinovac Research and Development Co., Ltd.), a subsidiary of Sinovac, has secured approximately US$500 million in funding for further development, capacity expansion and manufacturing of the CoronaVac, its COVID-19 vaccine candidate, as well as conduct other dev

Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development

Researchers believe the vaccine, which is already approved in China, could be “suitable for emergency use during the pandemic,” though further clinical trials will be needed.

Sinovac's Covid-19 Vaccine Appears Safe And Prompts ‘Quick' Immune Response, Study Finds

Brazilian health regulator has decided to halt clinical trials of a frontrunning Chinese vaccine following a “severe adverse event” observed in a participant, Bloomberg reported Monday.

Sinovac COVID-19 Vaccine Trial Halted In Brazil Over Adverse Event

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Fourth Intermediate People’s Court of Beijing (“Beijing Fourth Court”) issued a judgement holding Sinobioway Bio-medicine Co., Ltd. (“Sinobioway Medicine”) and Mr. Aihua Pan (collectively, “the Defendants”) liable for torts and breaches of shareholder fiduciary duty. The judgment follows a complaint filed by Sinovac Biotech

News for Sinovac Biotech Stock (SVA)